Breaking News Instant updates and real-time market news.

UNVR

Univar

$25.89

0.22 (0.86%)

06:11
11/06/18
11/06
06:11
11/06/18
06:11

Univar sees FY18 adj. EPS approximately $1.60, consensus $1.70

  • 06

    Nov

UNVR Univar
$25.89

0.22 (0.86%)

09/04/18
09/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. UPS (UPS) upgraded to Strong Buy from Market Perform at Raymond James with analyst Patrick Tyler Brown saying he believes investors are underappreciating UPS' long-term Domestic EBIT and 2021 free cash flow outlook, which could be greater than $8B. 2. Qualcomm (QCOM) upgraded to Outperform from Neutral at Macquarie with analyst Srini Pajjuri saying he believes risk/reward is attractive and sees multiple catalysts ahead including a final settlement with Huawei in the near future, increasing probability of an Apple (AAPL) settlement, and a 5G cycle that is not fully reflected in consensus estimates. 3. Albemarle (ALB) upgraded to Buy from Hold at SunTrust with analyst James Sheehan saying investors have driven down the price of the stock amid lithium oversupply concern on incorrect assumption that it is a commodity. 4. Univar (UNVR) upgraded to Buy from Hold at Berenberg with analyst Thomas Burlton saying the company is improving its conversion margin and EBITDA growth while its cash generation is also getting better. 5. Boston Scientific (BSX) upgraded to Buy from Hold at Jefferies with analyst Raj Denhoy citing a survey of 25 U.S. transcatheter aortic valve replacement doctors to gauge interest in tBoston Scientific's Lotus value. While feedback was better for Edwards Lifesciences (EW) and Medtronic's (MDT) valves, the majority of respondents were still interested in trying Lotus and expected the valve to capture 16%-18% share of the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/18
WELS
09/18/18
NO CHANGE
WELS
Outperform
Wells views Univar acquisition of Nexeo Solutions favorably
Wells Fargo analyst Allison Poliniak-Cusic views Univar's (UNVR) acquisition of Nexeo Solutions (NXEO) favorably given the overlap with Univar's "ongoing focus on profitable scale through technical sales, product breadth and deeper market penetration in areas like personal care." She believes Univar paid a fair price and is now poised to become a global chemical distribution leader. The analyst keeps an Outperform rating on the shares with a $40 price target.
09/18/18
JEFF
09/18/18
NO CHANGE
Target $39
JEFF
Buy
Univar acquisition of Nexeo brings 'compelling' synergies, says Jefferies
Jefferies analyst Laurence Alexander believes Univar's (UNVR) acquisition of Nexeo Solutions (NXEO) brings "compelling" synergies and free cash flow accretion. The deal is a "logical evolution" for the North American chemical distribution market, "albeit one with significant near-term hurdles," Alexander tells investors in a research note. He estimates earnings accretion by year three of 69c per share and free cash flow accretion of 50c per share. Alexander keeps a Buy rating on Univar with a $39 price target.
09/18/18
RHCO
09/18/18
DOWNGRADE
RHCO
Hold
Nexeo Solutions downgraded to Hold from Buy at SunTrust
Nexeo Solutions (NXEO) is being acquired by Univar (UNVR) in a deal worth $2B.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.